CN106074444A - Lepidinm meyenii Walp microcapsule powder as well as preparation method and application thereof - Google Patents
Lepidinm meyenii Walp microcapsule powder as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN106074444A CN106074444A CN201610495258.2A CN201610495258A CN106074444A CN 106074444 A CN106074444 A CN 106074444A CN 201610495258 A CN201610495258 A CN 201610495258A CN 106074444 A CN106074444 A CN 106074444A
- Authority
- CN
- China
- Prior art keywords
- meyenii walp
- lepidinm meyenii
- microcapsule powder
- weight ratio
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 67
- 239000003094 microcapsule Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000341 volatile oil Substances 0.000 claims abstract description 34
- 239000007962 solid dispersion Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 14
- 239000000741 silica gel Substances 0.000 claims abstract description 13
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 13
- 238000010298 pulverizing process Methods 0.000 claims abstract description 12
- 238000005516 engineering process Methods 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 238000009835 boiling Methods 0.000 claims abstract description 9
- 239000012530 fluid Substances 0.000 claims abstract description 9
- 235000011837 pasties Nutrition 0.000 claims abstract description 9
- 238000004090 dissolution Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 235000008098 Oxalis acetosella Nutrition 0.000 claims abstract description 6
- 235000010240 Paullinia pinnata Nutrition 0.000 claims abstract description 6
- 230000035558 fertility Effects 0.000 claims abstract description 6
- 230000036039 immunity Effects 0.000 claims abstract description 6
- 230000036299 sexual function Effects 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 241001119526 Paullinia Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 241001119522 Paullinia pinnata Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 23
- 239000007789 gas Substances 0.000 description 11
- 239000011734 sodium Substances 0.000 description 10
- 241000219780 Pueraria Species 0.000 description 9
- 230000027326 copulation Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000013011 mating Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009863 impact test Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a kind of Lepidinm meyenii Walp microcapsule powder improving stability of volatile oil and bioavailability, and its preparation method comprises the following steps: A, low-temperature airflow are pulverized: Lepidinm meyenii Walp uses low-temperature airflow crushing technology carry out fine powder that wall breaking pulverization is 800 1200 mesh；B, inclusion: be in molar ratio 1: 11: 3 ratio weigh G β CD, add 25 times amount water and grind well, add the Lepidinm meyenii Walp fine powder that step A prepares, grind to form cold drying after pasty state；C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 0.5% 5%, strength is ground 45 hours so that it is be uniformly dispersed；D, microencapsulation: put in fluid bed by the solid dispersion that step C prepares, take the CMC Na that weight ratio is 0.5% 2%, and with adding after water dissolution in fluidized bed, boiling makes its abundant microencapsulation.This Lepidinm meyenii Walp microcapsule powder is for preparing resisting fatigue, raising immunity, improvement sleep, improving sexual function, the raising medicine of fertility rate, health product, functional bread and cheese.
Description
Technical field
The present invention relates to a kind of microcapsule powder, particularly relate to a kind of agate significantly improving stability of volatile oil and bioavailability
Coffee microcapsule powder.
Background technology
Lepidinm meyenii Walp is the crucifer originating in more than 4000 meters of South America Peru Andes, present domestic Yunnan, new
There is plantation on the ground such as boundary.For nutritional labeling, Lepidinm meyenii Walp rich in proteins, aminoacid, unsaturated fatty acid and several mineral materials, closely
Become the nutrition food materials on compatriots' dining table over Nian and receive much concern；For health care, Lepidinm meyenii Walp is different from other Cruciferae
Being mainly characterized by of plant: Lepidinm meyenii Walp, in growth course, can be produced " functional secondary metabolism product by external environment stimulation
Thing "------volatile oil (compound such as amide containing class, alkaloid, glucosinolate and derivant thereof), this distinguishing feature
Determine that Lepidinm meyenii Walp has specific health care and (resisting fatigue, regains one's strength of body, improves immunity, increases sperm quality, improves sexual impotence early
Let out, improve the aspects such as sleep, anti-climacteric, active fertility and hypermnesis there is good effect).
" volatile oil " not Lepidinm meyenii Walp self is peculiar, but is stimulated by external environment during growth metabolism and produce, and it contains
Amount height is closely related with its growth metabolism process.At present, the exploitation around Lepidinm meyenii Walp " volatile oil " is applied and be there are two big technology bottles
Neck: first, volatile oil belongs to extremely unstable compound, gathering, high temperature drying, storage, can quickly volatilization decline in the course of processing
Exhaust totally；Secondly, volatile oil belongs to liposoluble constituent, and directly edible absorption rate is extremely low.The two technical bottleneck restricts
The Depth Study of Lepidinm meyenii Walp industry, develop, apply.
Summary of the invention
The technical problem to be solved is: overcome techniques described above bottleneck, it is provided that one significantly improves volatilization
The Lepidinm meyenii Walp microcapsule powder of oil-proofness and bioavailability, makes full use of functional maca volatile oil component, is promoting Lepidinm meyenii Walp health care
While function, significantly shorten health care effective time.
In order to solve techniques described above problem, the present invention provides one to significantly improve stability of volatile oil and biological utilisation
The Lepidinm meyenii Walp microcapsule powder of degree, and the preparation method of described microcapsule powder and purposes.
The purpose of the present invention realizes by the following technical solutions.
The present invention provides a kind of method of Lepidinm meyenii Walp microcapsule powder prepared and significantly improve stability of volatile oil and bioavailability,
Described method specifically includes following steps:
A, low-temperature airflow wall breaking pulverization: use low-temperature airflow wall breaking pulverization technology, by Lepidinm meyenii Walp wall breaking pulverization to 800-1200
Mesh fine powder, on the premise of avoiding loss of volatile oil to greatest extent, it is ensured that it fully exosmoses and separates out outside cell wall；
B, inclusion: be in molar ratio 1: 1-1: 3 ratio weigh G-β-CD, add 2-5 times amount water and grind well, add step
The described fine powder that A prepares, grinds to form cold drying after pasty state；
C, solid dispersion: step B is by weight the gas phase micropowder silica gel of addition 0.5%-5%, and after mixing, strength is ground
4-5 hour so that it is be uniformly dispersed, form solid dispersion；
D, microencapsulation: the described solid dispersion that step C prepares is put in fluid bed, is 0.5%-2%'s by weight ratio
After CMC-Na water dissolution, adding in fluidized bed, boiling makes its abundant microencapsulation, thus obtains described Lepidinm meyenii Walp microcapsule powder.
As preferably, in step B, the G-β-CD amount of taking is mol ratio 1: 1-1: 2；The gas phase micropowder silica gel amount of taking in step C
For weight ratio 1-3%；In D step, the CMC-Na amount of taking is weight ratio 0.5-1%.
Further preferably, in step B, the G-β-CD amount of taking is mol ratio 1: 1；In step C, the gas phase micropowder silica gel amount of taking is
Weight ratio 2%；In D step, the CMC-Na amount of taking is weight ratio 0.5%.
Lepidinm meyenii Walp microcapsule powder of the present invention can be used directly, it is possible to add pharmaceutically acceptable adjuvant make powder,
The multiple dosage forms such as tablet, capsule, granule or pill, are used for preparing resisting fatigue, improving immunity, improvement sleep, the property improved
Function, the raising medicine of fertility rate, health product, functional bread and cheese.
The present invention uses low-temperature airflow wall breaking pulverization to guarantee its precipitation of fully exosmosing while avoiding volatile oil exhaustion, then
The volatile oil gone out with the G-external dialysis of β-CD carries out abundant inclusion, by inclusion, with the G-β-CD of macromole space net structure
For carrier, little molecule volatile oil component is substantially embedded in the netted hole of G-β-CD, thus has cut off unstable little molecularization
Compound contacts with surrounding, makes volatile oil component be adequately protected, and forms embedded clathrate, and water solublity significantly carries
Height, and mask the volatile oil bad smell of Lepidinm meyenii Walp, reduce zest and toxic and side effects；Use gas phase micropowder silica gel to inclusion again
Thing disperses, and makes solid dispersion, can improve solubility property further, improves dissolution rate, improves bioavailability, and
Prepared clathrate is formed homogeneously dispersed state, it is simple to microencapsulation processes further；CMC-Na is finally used to carry out microencapsulation
Process, stability of volatile oil can be improved further, cover bad smell.
Therefore, Lepidinm meyenii Walp microcapsule powder of the present invention compared with prior art, at least has the advantages that (1) is effective
Prevent volatile oil component to scatter and disappear, significantly improve stability of volatile oil；(2) volatile oil dissolubility significantly improves；(3) effectively cover and wave
Hair oil bad smell；(4) rate of release of effective regulatory function composition (volatile oil)；(5) zest and toxic and side effects are reduced；
(6) bioavailability is improved；(7) absorption and effective time are significantly shortened.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but never in any form the present invention is limited
System, based on present invention teach that any conversion or improvement made, each falls within protection scope of the present invention.
Embodiment 1
A, low-temperature airflow are pulverized: use low-temperature airflow crushing technology, by the fine powder that Lepidinm meyenii Walp wall breaking pulverization is 800 mesh, make to wave
Hair oil fully exosmoses precipitation；
B, inclusion: be in molar ratio 1: 1 ratio weigh G-β-CD, add 2 times amount water and grind well, add step A prepare
Lepidinm meyenii Walp fine powder, grind to form cold drying after pasty state；
C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 0.5%, strength is ground 4 hours so that it is
It is uniformly dispersed；
D, microencapsulation: put in fluid bed by the solid dispersion that step C prepares, take the CMC-Na that weight ratio is 0.5%, use
Adding after water dissolution in fluidized bed, boiling makes its abundant microencapsulation, obtains described Lepidinm meyenii Walp microcapsule powder.
Embodiment 2
A, low-temperature airflow are pulverized: use low-temperature airflow crushing technology, by the fine powder that Lepidinm meyenii Walp wall breaking pulverization is 900 mesh, make to wave
Hair oil fully exosmoses precipitation；
B, inclusion: be in molar ratio 1: 2 ratio weigh G-β-CD, add 3 times amount water and grind well, add step A prepare
Lepidinm meyenii Walp fine powder, grind to form cold drying after pasty state；
C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 1%, strength is ground 5 hours so that it is
It is uniformly dispersed；
D, microencapsulation: the solid dispersion that step C prepares is put in fluid bed, takes the CMC-Na that weight ratio is 1%, use water
Adding after dissolving in fluidized bed, boiling makes its abundant microencapsulation, obtains described Lepidinm meyenii Walp microcapsule powder.
Embodiment 3
A, low-temperature airflow are pulverized: use low-temperature airflow to pulverize, Lepidinm meyenii Walp carries out the fine powder that wall breaking pulverization is 1000 mesh, makes to wave
Hair oil fully exosmoses precipitation；
B, inclusion: be in molar ratio 1: 3 ratio weigh G-β-CD, add 4 times amount water and grind well, add step A prepare
Lepidinm meyenii Walp fine powder, grind to form cold drying after pasty state；
C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 3%, strength is ground 4 hours so that it is
It is uniformly dispersed；
D, microencapsulation: put in fluid bed by the solid dispersion that step C prepares, take the CMC-Na that weight ratio is 1.5%, use
Adding after water dissolution in fluidized bed, boiling makes its abundant microencapsulation, obtains described Lepidinm meyenii Walp microcapsule powder.
Embodiment 4
A, low-temperature airflow are pulverized: use low-temperature airflow crushing technology, by the fine powder that Lepidinm meyenii Walp wall breaking pulverization is 1100 mesh, make to wave
Hair oil fully exosmoses precipitation；
B, inclusion: be in molar ratio 1: 2 ratio weigh G-β-CD, add 5 times amount water and grind well, add step A prepare
Lepidinm meyenii Walp fine powder, grind to form cold drying after pasty state；
C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 4%, strength is ground 5 hours so that it is
It is uniformly dispersed；
D, microencapsulation: the solid dispersion that step C prepares is put in fluid bed, takes the CMC-Na that weight ratio is 2%, use water
Adding after dissolving in fluidized bed, boiling makes its abundant microencapsulation, obtains described Lepidinm meyenii Walp microcapsule powder.
Embodiment 5
A, low-temperature airflow are pulverized: use low-temperature airflow crushing technology, by the fine powder that Lepidinm meyenii Walp wall breaking pulverization is 1200 mesh, make to wave
Hair oil fully exosmoses precipitation；
B, inclusion: be in molar ratio 1: 1 ratio weigh G-β-CD, add 5 times amount water and grind well, add step A prepare
Lepidinm meyenii Walp fine powder, grind to form cold drying after pasty state；
C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 5%, strength is ground 4 hours so that it is
It is uniformly dispersed；
D, microencapsulation: put in fluid bed by the solid dispersion that step C prepares, take the CMC-Na that weight ratio is 0.5%, use
Adding after water dissolution in fluidized bed, boiling makes its abundant microencapsulation, obtains described Lepidinm meyenii Walp microcapsule powder.
Embodiment 6
A, low-temperature grinding: use low-temperature airflow crushing technology, by the fine powder that Lepidinm meyenii Walp wall breaking pulverization is 1000 mesh, make volatile oil
Fully extravasation；
B, inclusion: be in molar ratio 1: 1 ratio weigh G-β-CD, add 3 times amount water and grind well, add step A prepare
Lepidinm meyenii Walp fine powder, grind to form cold drying after pasty state；
C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 2%, strength is ground 4 hours so that it is
It is uniformly dispersed；
D, microencapsulation: put in fluid bed by the solid dispersion that step C prepares, take the CMC-Na that weight ratio is 0.5%, use
Adding after water dissolution in fluidized bed, boiling makes its abundant microencapsulation, obtains described Lepidinm meyenii Walp microcapsule powder.
Embodiment 7
Take Lepidinm meyenii Walp microcapsule powder obtained in above-mentioned any embodiment, add medicine, health product or functional bread and cheese
Acceptable adjuvant, through granulation, tabletting, obtains tablet；Or through pelletizing, drying, fill to capsule, obtain capsule；Or
Person, through pelletizing, drying, obtains granule；Or through pill, drying, obtain pill.
Described medicine, health product or functional bread and cheese acceptable adjuvant, can be diluent, excipient, fill out
Fill agent, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier and lubricant.
Lepidinm meyenii Walp microcapsule powder Dependent Stability of the present invention and bioavailability study situation are as follows:
With the embodiment of the present invention 6 gained Lepidinm meyenii Walp microcapsule powder, carry out stability test, absorbance examination with common Lepidinm meyenii Walp fine powder
Test, and on mice sexual behaviour impact test, and result is compared, specific as follows:
Test specimen: the 1. embodiment of the present invention 6 gained Lepidinm meyenii Walp microcapsule powder；2. common pueraria root powder.
(1) stability test
1, prepared by sample: take above-mentioned two sample respectively, and each dress is 100g/ bag, is designated as 1, No. 2.
2, test specimen is placed 6 months under conditions of temperature 40 DEG C, relative humidity 75%, be accelerated stability examination
Test (2010 editions " Chinese Pharmacopoeia " two, P annex 200), respectively at 0 month, 1 month, 2 months, 3 months, sampling in 6 months, survey
Determine volatile oil content；
3, volatile oil content testing method: take each 10g of sample, adds 100mL water, mixing be followed by volatile oil extractor and
Reflux condensing tube, extracts according to volatile oil is drawn standard method (2010 editions " Chinese Pharmacopoeia ", P annex 63), extracts
Time is 8h, uses 45 DEG C of absolute ether extractions heavily steamed distillate containing volatile oil, and ether extraction liquid passes through anhydrous sodium sulfate
After drying, 45 DEG C of recovery absolute ethers constant volume, to 20mL, detect with gas chromatograph-mass spectrometer；
Detection method: the benzene acetonitrile standard solution of preparation 0.1mol/L, carries out gas chromatography mass spectrometry detection, wherein vapor detection ginseng
Number is as follows: HP-5MS fused-silica capillary column (30m × 0.25mm, 0.25 μm), and heating schedule is 35 DEG C and maintains 2min, with 15
DEG C/min rises to 215 DEG C, keeps 16min；Carrier gas (He) flow velocity 1.0mL/min, pressure 2.4kPa, sample size 1.0 μ L；Split ratio
50∶1；
Mass Spectrometer Method condition is as follows: MSD Chemstation E.01.00.237 work station, electron bombardment (EI) ion
Source；Ion source temperature 230 DEG C, ionization voltage 70eV；Transmission line temperature 275 DEG C；Mass scan range 50～500m/z, scanning speed
Rate 2scans/s；Parent ion 285m/z；Activate voltage 1.5V.
Result of the test is shown in Table one:
Table one
Result of the test shows: Lepidinm meyenii Walp microcapsule powder of the present invention (1. number sample) volatile oil content in 12 months is stable,
Change inconspicuous when 24 months, only exhaustion 2.26%；Common pueraria root powder (2. number sample) volatile oil content is the most steady in 3 months
Fixed, but after 3 months, content substantially reduces, and during to off-test, content is only 0.04%, and exhaustion rate is 97.67%
(2) absorbance test
2. number 1, prepared by sample: take above-mentioned two sample respectively, is designated as 1.,；
2, test method: experimental animal uses the healthy rabbits of body weight about 3kg (to be carried by Sichuan University's Experimental Animal Center
For), animal is randomly divided into four groups, and in advance after fasting 12h, gavage gives above-mentioned sample respectively, and dosage is that 200mg/kg (is equivalent to
70kg Coming-of-Age Day taking dose 4g), volatile oil content in intensive mensuration blood plasma after giving sample, to peak time half an hour after,
Detection blood peak concentration of drug (Cmax)；
After test specimen gavage terminates, drug withdrawal a period of time, to the complete metabolism of animal vivo sample, then intravenous injection is given
The dosage volatile oil solution such as give, and measure volatile oil content in blood plasma (μ g/mL), in this, as reference data；
The results are shown in Table two:
Table two
Result of the test shows: in Lepidinm meyenii Walp microcapsule powder of the present invention (1. number sample), volatile oil absorbance is the highest, for commonly
3.92 times of pueraria root powder (2. number sample).
(3) test on mice sexual behaviour impact
2. number 1, prepared by sample: take above-mentioned two sample respectively, is designated as 1.,；
2, test method: experimental animal uses Kunming mouse, and cleaning grade, male and female have concurrently, and body weight 18～22g is (by Sichuan
University's Experimental Animal Center provides)；Male mice is randomly divided into matched group and two test group, often group 10.Two test group
Gavage gives above-mentioned sample respectively, and dosage is 200mg/kg (being equivalent to 70kg Coming-of-Age Day taking dose 4g), and matched group gavage is given
Dosage normal saline, the continuous gavage 120 days such as give, carried out tests below respectively at the 30th day, the 60th day, the 90th day, the 120th day
Observe: 48h female sub-cutaneous injections estradiol benzoate (0.02mg/ only) before test, make rutting period identical, tested evening 7～
Carry out when 11, male mice is placed individually in cage (55cm × 35cm × 20cm) 5min so that it is adapt to environment, then by 1: 3
Hero Mus is mated by ratio with female Mus, observed and recorded copulation incubation period (from female Mus put into male Mus the 1st time and female Mus copulation time
Between) and 1h in number of copulations；
The results are shown in Table three and table four:
The impact on male mice mating incubation period (s) of the table three different tests sample
Note: compare with matched group, (P value is statistically to represent that real result degree (can to * P ＜ 0.05, * * P ＜ 0.01
Represent overall) a kind of method of estimation.P ＜ 0.05 indicates that significant difference, P ＜ 0.01 indicate notable significant difference.
The impact on male mice mating number of times (in 1h) of the table four different tests sample
Note: compare with matched group, (P value is statistically to represent that real result degree (can to * P ＜ 0.05, * * P ＜ 0.01
Represent overall) a kind of method of estimation.P ＜ 0.05 indicates that significant difference, P ＜ 0.01 indicate notable significant difference.
Result of the test:
(1) copulation incubation period
Lepidinm meyenii Walp microcapsule powder of the present invention (1. number sample) the 30th, 60,90,120 days copulation incubation periods of test with compare
Group is compared, and all has notable significant difference；Common pueraria root powder (2. number sample) only the 90th, 120 days copulation incubation periods with compare
There were significant differences for group ratio.To sum up, copulation onset time incubation period (30 days) of Lepidinm meyenii Walp microcapsule powder (1. number sample) is better than commonly
Pueraria root powder (2. number sample) (90 days).
(2) mating number of times
Lepidinm meyenii Walp microcapsule powder of the present invention (1. number sample) test the 30th, 60,90,120 days 1h in mating number of times with right
Compare according to group, all have significant difference；Common pueraria root powder (2. number sample) only in the 90th, 120 days 1h mating number of times with compare
There were significant differences for group ratio.To sum up, in the 1h of Lepidinm meyenii Walp microcapsule powder (1. number sample), mating number of times onset time (30 days) is better than general
Logical pueraria root powder (2. number sample) (90 days).
This result of the test shows: the effective time of Lepidinm meyenii Walp microcapsule powder of the present invention (1. number sample) compares common pueraria root powder
(2. number sample) shortens 1/3.
Above correlation test result shows, the stability of Lepidinm meyenii Walp microcapsule powder of the present invention and absorbance are significantly larger than common
Pueraria root powder, onset time is greatly shortened.
Although being described above the multiple detailed description of the invention of the present invention, but the present invention being not limited to this.Without departing from this
On the premise of spirit and essence, member of ordinary skill in the art can carry out the deformation of various equivalence to the present invention and change
Dynamic, and these deformation and change are all in scope.
Claims (8)
1. the method preparing the Lepidinm meyenii Walp microcapsule powder improving stability of volatile oil and bioavailability, it is characterised in that described
Method specifically includes following steps:
A, low-temperature airflow are pulverized: use low-temperature airflow crushing technology, by the fine powder that Lepidinm meyenii Walp wall breaking pulverization is 800-1200 mesh, make to wave
Hair oil fully exosmoses precipitation；
B, inclusion: be in molar ratio 1: 1-1: 3 ratio weigh G-β-CD, add 2-5 times amount water and grind well, add step A system
The described fine powder obtained, grinds to form cold drying after pasty state；
C, solid dispersion: after adding the gas phase micropowder silica gel mixing that weight ratio is 0.5%-5%, strength is ground 4-5 hour,
Make it be uniformly dispersed；
D, microencapsulation: put in fluid bed by the solid dispersion that step C prepares, take the CMC-Na that weight ratio is 0.5%-2%, use
Adding after water dissolution in fluidized bed, boiling makes its abundant microencapsulation, thus obtains described Lepidinm meyenii Walp microcapsule powder.
Method the most according to claim 1, it is characterised in that in step B, the G-β-CD amount of taking is mol ratio 1: 1.
3. according to the method described in claim 1-2 any one, it is characterised in that the gas phase micropowder silica gel amount of taking in step C
For weight ratio 2%.
4. according to the method described in claim 1-3 any one, it is characterised in that in D step, the CMC-Na amount of taking is weight
Ratio 0.5%.
5. the preparation including the Lepidinm meyenii Walp microcapsule powder prepared by method described in any one of claim 1-4, it is characterised in that
Described Lepidinm meyenii Walp microcapsule powder is separately added into the adjuvant that medicine, health product or functional bread and cheese can accept and makes tablet, capsule
Agent, granule or pill.
6. the Lepidinm meyenii Walp microcapsule powder that a kind is prepared by method described in any one of claim 1-4 is in preparation resisting fatigue, raising immunity
Power, improve sleep, improve sexual function, improve fertility rate medicine in application.
7. the Lepidinm meyenii Walp microcapsule powder that a kind is prepared by method described in any one of claim 1-4 is in preparation resisting fatigue, raising immunity
Power, improve sleep, improve sexual function, improve fertility rate health product in application.
8. the Lepidinm meyenii Walp microcapsule powder that a kind is prepared by method described in any one of claim 1-4 is in preparation resisting fatigue, raising immunity
Power, improve sleep, improve sexual function, improve fertility rate functional bread and cheese in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610495258.2A CN106074444A (en) | 2016-06-21 | 2016-06-21 | Lepidinm meyenii Walp microcapsule powder as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610495258.2A CN106074444A (en) | 2016-06-21 | 2016-06-21 | Lepidinm meyenii Walp microcapsule powder as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106074444A true CN106074444A (en) | 2016-11-09 |
Family
ID=57213800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610495258.2A Pending CN106074444A (en) | 2016-06-21 | 2016-06-21 | Lepidinm meyenii Walp microcapsule powder as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074444A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107137443A (en) * | 2017-04-26 | 2017-09-08 | 丽江久康生物科技有限公司 | A kind of composition for relieving fatigue, preparation method and applications |
| CN107913296A (en) * | 2017-12-14 | 2018-04-17 | 云南德彩堂生物医药科技有限公司 | A kind of attached raw material of the high physiological activity quinoa of high stable and preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1473594A (en) * | 2003-07-01 | 2004-02-11 | 华中科技大学 | Extract of Maka root |
| CN103977053A (en) * | 2014-05-16 | 2014-08-13 | 云南德彩堂生物医药科技有限公司 | Maca composition with high stability and high bioavailability |
| CN105455132A (en) * | 2015-12-05 | 2016-04-06 | 浙江百龄芝草生物科技有限公司 | Maca and ganoderma lucidum buccal tablets and preparation method thereof |
-
2016
- 2016-06-21 CN CN201610495258.2A patent/CN106074444A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1473594A (en) * | 2003-07-01 | 2004-02-11 | 华中科技大学 | Extract of Maka root |
| CN103977053A (en) * | 2014-05-16 | 2014-08-13 | 云南德彩堂生物医药科技有限公司 | Maca composition with high stability and high bioavailability |
| CN105455132A (en) * | 2015-12-05 | 2016-04-06 | 浙江百龄芝草生物科技有限公司 | Maca and ganoderma lucidum buccal tablets and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107137443A (en) * | 2017-04-26 | 2017-09-08 | 丽江久康生物科技有限公司 | A kind of composition for relieving fatigue, preparation method and applications |
| CN107913296A (en) * | 2017-12-14 | 2018-04-17 | 云南德彩堂生物医药科技有限公司 | A kind of attached raw material of the high physiological activity quinoa of high stable and preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107307403B (en) | Astaxanthin micro-nano solid preparation | |
| CN101524377B (en) | Composite of wall-breaking lucidum spore powder and cyclodextrin and preparation method thereof | |
| CN102458434B (en) | Composition for increasing the bioavailability of saponin | |
| CN103652859B (en) | A kind of health food with anti-oxidation function and preparation method thereof | |
| CN105455132B (en) | A kind of maca lucid ganoderma buccal tablets and preparation method thereof | |
| CN102459623B (en) | Methods for preparing a fermented ginseng concentrate or powder | |
| CN106074444A (en) | Lepidinm meyenii Walp microcapsule powder as well as preparation method and application thereof | |
| CN102327234B (en) | Racecadotril suspension | |
| CN103977053A (en) | Maca composition with high stability and high bioavailability | |
| CN104837366A (en) | Composition comprising natural polyphenol compounds, and composition for oral administration comprising same | |
| CN101926840A (en) | Ultrafine powder of echinacea and preparation method and application thereof | |
| KR101722165B1 (en) | A method of preparation of neohesperidin dihydrochalcone from citrus peel by using supercritical fluid extraction | |
| CN103520111B (en) | A kind of florfenicol dry suspension and its production and use | |
| CN103435496A (en) | Bromhexine hydrochloride compound, and preparation method, medicinal composition and preparation thereof | |
| CN105326880A (en) | Rape pollen water soluble extract as well as preparation method and application thereof | |
| CN106913589A (en) | A kind of haematococcus pluvialis solid dispersions, Preparation Method And The Use | |
| CN103535734B (en) | Bagged instant preparation of a kind of improving water flood and preparation method thereof | |
| CN113016844B (en) | Wild jujube seed extract with coffee flavor and liver protection, and preparation method and application thereof | |
| CN108066350A (en) | The application of forsythin, its derivative, forsythin and phillygenol composition in prevention, treatment senile dementia is prepared | |
| CN107137443A (en) | A kind of composition for relieving fatigue, preparation method and applications | |
| CN102406897B (en) | Xingnaojing solid medicinal composition and preparation method thereof | |
| CN102258547B (en) | Hazel leaf flavone extract and medicinal composition thereof | |
| CN107496510B (en) | Cyclocarya paliurus capsule and preparation method thereof | |
| CN106387915B (en) | Qi and coffee vigor-benefiting effervescent tablet and preparation process and application thereof | |
| CN110038090A (en) | A kind of compound celery oil self-emulsifying soft capsule and preparation method thereof with antigout effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |
|
| RJ01 | Rejection of invention patent application after publication |